Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BO-112 |
| Synonyms | |
| Therapy Description |
BO-112 is a nanoparticle formulation of a synthetic double stranded RNA (poly I:C) complex, which potentially enhances anti-tumor immune response, induces apoptosis, and decreases tumor growth (PMID: 31046839). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BO-112 | BO 112|BO112 | BO-112 is a nanoparticle formulation of a synthetic double stranded RNA (poly I:C) complex, which potentially enhances anti-tumor immune response, induces apoptosis, and decreases tumor growth (PMID: 31046839). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06422936 | Phase II | BO-112 | Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (SPOTLIGHT204) | Recruiting | ISR | ESP | 0 |